Zhitong Finance App News, Shandong Xinhua Pharmaceutical Co., Ltd. (00719) issued an announcement. Recently, Shandong Zibo Xinda Pharmaceutical Co., Ltd. (hereinafter referred to as “Xinda Pharmaceutical”), a wholly-owned subsidiary of Shandong Xinhua Pharmaceutical Co., Ltd., received the approval and issuance of donepezil hydrochloride tablets (hereinafter referred to as “this product”) “Drug Registration Certificate” by the State Drug Administration.

In February 2025, Xinda Pharmaceuticals submitted marketing license application data for donepezil hydrochloride to the Drug Evaluation Center (CDE) of the China Drug Administration and was accepted. It obtained the “Drug Registration Certificate” in September 2026. The review concluded that registration was approved.

This product is used to treat mild, moderate, or severe symptoms of Alzheimer's disease.

This product belongs to category B of the “National Catalogue of Drugs for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2025)”. According to relevant statistics, sales of donepezil preparations in public medical institutions in China will be approximately RMB 620 million in 2025.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.